Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
SMC2811 07/07/2025 lecanemab (Leqembi) Resubmission

For treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease in adult patients that are apolipoprotein E ɛ 4 (ApoEɛ4) heterozygotes or non-carriers.

SMC2767 07/07/2025 pembrolizumab (Keytruda) Full

In combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.

SMC2764 07/07/2025 abaloparatide (Eladynos) Full

Treatment of osteoporosis in postmenopausal women at increased risk of fracture.

SMC2798 07/07/2025 fezolinetant (Veoza) Full

For the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

SMC2736 07/07/2025 osimertinib (Tagrisso) Full

In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

SMC2733 07/07/2025 selpercatinib (Retsevmo) Full

As monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).

SMC2758 07/07/2025 amivantamab (Rybrevant) Full

In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.

SMC2813 09/06/2025 pegzilarginase (Loargys) Non submission

Treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older.

SMC2812 09/06/2025 pegylated liposomal irinotecan (Onivyde) Non submission

In combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas

SMC2756 09/06/2025 sumatriptan (Suvexx®) Abbreviated

The acute treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient.

SMC2732 09/06/2025 selpercatinib (Retsevmo) Full

As monotherapy for the treatment of adults and adolescents 12 years and older with advanced rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).

SMC2750 09/06/2025 ruxolitinib (Jakavi) Full

Treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids.

SMC2740 09/06/2025 bempedoic (Nilemdo) Non submission

In adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:

SMC2741 09/06/2025 bempedoic acid / ezetimibe (Nustendi) Non submission

in adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:
• in patients on a maximum tolerated dose of a statin and not adequately controlled with additional ezetimibe treatment or,
• in patients who are either statin-intolerant, or for whom a statin is contraindicated, and not adequately controlled with ezetimibe treatment or,
• in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets.

SMC2751 09/06/2025 cladribine (Mavenclad) Full

Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease as defined by clinical or imaging features.

SMC2744 09/06/2025 bevacizumab gamma (Lytenava) Abbreviated

In adults for treatment of neovascular (wet) age-related macular degeneration (nAMD)

SMC2735 09/06/2025 durvalumab (Imfinzi) Full

In combination with tremelimumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma.

SMC2765 12/05/2025 mepolizumab (Nucala) Abbreviated

Add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.

SMC2748 12/05/2025 fruquintinib (Fruzaqla) Full

As monotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-vascular endothelial growth factor (VEGF) therapy and, if rat sarcomas virus (RAS) wildtype and medically appropriate, an anti-epidermal growth factor receptor (EGFR) therapy.

SMC2738 12/05/2025 erdafitinib (Balversa) Full

As monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations who have previously received at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-(L)1) inhibitor in the unresectable or metastatic treatment setting.

Load more
Publication due date SMC meeting date Medicine Submission Type Indication
11/08/2025 mirikizumab (Omvoh) Abbreviated

For the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

11/08/2025 zanubrutinib (Brukinsa) Abbreviated

As monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy

11/08/2025 01/07/2025 brentuximab vedotin (Adcetris) Full

Treatment of adult patients with previously untreated cell membrane receptor 30-positive (CD30+) Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).

TBC 03/09/2024 maralixibat (Livmarli) Full

For treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older.

TBC TBC ribociclib (Kisqali) Full

In combination with an aromatase inhibitor is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence.s

In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

TBC TBC maralixibat (Livmarli) Resubmission

Indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older.

TBC TBC blinatumomab (Blincyto) Full

Treatment of adult patients with Philadelphia chromosome (Ph)-negative, CD19-positive, B-cell precursor acute lymphoblastic leukaemia (ALL) in the consolidation phase.

TBC TBC durvalumab (Imfinzi) Full

In combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:

  • durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)
  • durvalumab in combination with olaparib in endometrial cancer that ismismatch repair proficient (pMMR).
TBC TBC dupilumab (Dupixent) Full

In adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.

TBC TBC delgocitinib (Anzupgo) Full

Treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids (TCS) are inadequate or inappropriate.

TBC TBC nivolumab (Opdivo) Full

In combination with ipilimumab (YERVOY®) (NIVO + IPI) is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) colorectal cancer (CRC) in the following settings: first-line treatment of unresectable or metastatic CRC.

TBC TBC marstacimab (Hympavzi) Full

For routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with:

  • severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%)
    without factor VIII inhibitors, or
  • severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without
    factor IX inhibitors

 

TBC TBC ripretinib (Qinlock) Resubmission

Treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

TBC TBC capivasertib (Truqap) Full

In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine based regimen.

TBC TBC nusinersen (Spinraza) Ultra-orphan reassessment

For treatment of 5q spinal muscular atrophy (SMA).

TBC TBC rucaparib (Rubraca) Full

As monotherapy for the maintenance treatment of adult patients with
advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

TBC TBC belantamab mafodotin (Blenrep) Full

In combination with pomalidomide and dexamethasone (BPd) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy including lenalidomide.

TBC TBC belantamab mafodotin (Blenrep) Full

In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

TBC TBC durvalumab (Imfinzi) Full

Treatment of adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).

TBC TBC ataluren (Translarna) Ultra-orphan reassessment

Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older.

The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

Load more